Fig. 1From: Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trialCONSORT diagram of patient disposition. Safety analyses were conducted in the all-patients-treated set, which included all randomized patients who received ≥ 1 infusion of double-blind study drug and had a visit in the extension period. Efficacy analyses were conducted in the full analysis set, which included all randomized patients who received ≥ 1 infusion of double-blind study drug, had a valid baseline assessment, and had ≥ 1 valid assessment of monthly migraine days in the extension periodBack to article page